Log in

Relevant bibliographies by topics / Antibody-toxin conjugates

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Antibody-toxin conjugates'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antibody-toxin conjugates.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antibody-toxin conjugates"

1

Esteva, Francisco J., Kathy D. Miller, and Beverly A. Teicher. "What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?" American Society of Clinical Oncology Educational Book, no. 35 (May 2015): e117-e125. http://dx.doi.org/10.14694/edbook_am.2015.35.e117.

Full text

Abstract:

Antibody conjugates are a diverse class of therapeutics that consist of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody conjugates has been marked by hurdles identified and overcome. Early conjugates used mouse antibodies, drugs that either were not sufficiently potent, were immunogenic (proteins), or were too toxic, and linkers that were not suffi

APA, Harvard, Vancouver, ISO, and other styles

2

Ahmad, Ateeq, and Kevin Law. "Strategies for designing antibody-toxin conjugates." Trends in Biotechnology 6, no. 10 (October 1988): 246–51. http://dx.doi.org/10.1016/0167-7799(88)90056-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Govindan, Serengulam V., and David M. Goldenberg. "New Antibody Conjugates in Cancer Therapy." Scientific World JOURNAL 10 (2010): 2070–89. http://dx.doi.org/10.1100/tsw.2010.191.

Full text

Abstract:

Targeting of radiation, drugs, and protein toxins to cancers selectively with monoclonal antibodies (MAbs) has been a topic of considerable interest and an area of continued development. Radioimmunotherapy (RAIT) of lymphoma using directly labeled MAbs is of current interest after approval of two radiolabeled anti-CD20 MAbs, as illustrated with the near 100% overall response rate obtained in a recent clinical trial using an investigational radiolabeled anti-CD22 MAb,90Y-epratuzumab. The advantage of pretargeted RAIT over directly labeled MAbs is continuing to be validated in preclinical models

APA, Harvard, Vancouver, ISO, and other styles

4

Liang, X. P., M. E. Lamm, and J. G. Nedrud. "Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus." Journal of Immunology 141, no. 5 (September 1, 1988): 1495–501. http://dx.doi.org/10.4049/jimmunol.141.5.1495.

Full text

Abstract:

Abstract Successful oral immunization to prevent infectious diseases in the gastrointestinal tract as well as distant mucosal tissues may depend on the effectiveness of an Ag to induce gut immune responses. We and others have previously reported that cholera toxin possesses strong adjuvant effects on the gut immune response to co-administered Ag. To explore further adjuvant effects of cholera toxin, the holotoxin or its B subunit was chemically cross-linked to Sendai virus. The resulting conjugates, which were not infectious, were evaluated for their capacity to induce gut immune responses aga

APA, Harvard, Vancouver, ISO, and other styles

5

Panjideh, Hossein, Nicole Niesler, Alexander Weng, and Hendrik Fuchs. "Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861." Toxins 14, no. 7 (July 13, 2022): 478. http://dx.doi.org/10.3390/toxins14070478.

Full text

Abstract:

Immunotoxins do not only bind to cancer-specific receptors to mediate the elimination of tumor cells through the innate immune system, but also increase target cytotoxicity by the intrinsic toxin activity. The plant glycoside SO1861 was previously reported to enhance the endolysosomal escape of antibody-toxin conjugates in non-hematopoietic cells, thus increasing their cytotoxicity manifold. Here we tested this technology for the first time in a lymphoma in vivo model. First, the therapeutic CD20 antibody obinutuzumab was chemically conjugated to the ribosome-inactivating protein dianthin. The

APA, Harvard, Vancouver, ISO, and other styles

6

Faria, Morse, Marlking Peay, Brandon Lam, Eric Ma, Moucun Yuan, Michael Waldron, William Mylott, Meina Liang, and Anton Rosenbaum. "Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2." Antibodies 8, no. 1 (January 11, 2019): 11. http://dx.doi.org/10.3390/antib8010011.

Full text

Abstract:

Bioanalysis of complex biotherapeutics, such as antibody-drug conjugates (ADCs), is challenging and requires multiple assays to describe their pharmacokinetic (PK) profiles. To enable exposure-safety and exposure-efficacy analyses, as well as to understand the metabolism of ADC therapeutics, three bioanalytical methods are typically employed: Total Antibody, Antibody Conjugated Toxin or Total ADC and Unconjugated Toxin. MEDI4276 is an ADC comprised of biparatopic humanized antibody attached via a protease-cleavable peptide-based maleimidocaproyl linker to a tubulysin toxin (AZ13599185) with an

APA, Harvard, Vancouver, ISO, and other styles

7

Yu, Rui, Junjie Xu, Tao Hu, and Wei Chen. "The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity." Mediators of Inflammation 2020 (July 4, 2020): 1–11. http://dx.doi.org/10.1155/2020/9596129.

Full text

Abstract:

The encapsulated bacteria, as Streptococcus pneumonia, Haemophilus influenzae type b, and Neisseria meningitidis, cause serious morbidity and mortality worldwide. The capsular polysaccharide (PS), which could elicit a weak T cell-independent immune response, is a vital virulence determinant. One of the strategies to improve the PS-specific immunogenicity is to conjugate PS with a nontoxic carrier protein. Tetanus toxoid (TT) and CRM197 are the typical carrier proteins for the PS conjugate vaccines. TT is the inactivated tetanus toxin manipulated with formaldehyde, which suffers from the pollut

APA, Harvard, Vancouver, ISO, and other styles

8

Marsh, J. W., and D. M. Neville. "A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins." Journal of Immunology 140, no. 10 (May 15, 1988): 3674–78. http://dx.doi.org/10.4049/jimmunol.140.10.3674.

Full text

Abstract:

Abstract Immunotoxins, constructed by chemically cross-linking an antibody and protein toxin, do not possess the high efficacy of the native toxin. Decreases in toxicity are due in part to the steric constraints imposed on the two macromolecules, which result in both decreased antibody binding and toxin function. In examining the structural features that influence efficacy in holotoxin-antibody conjugates, it was found that the incorporation of a 29-residue polypeptide, derived from the insulin B chain between the antibody and ricin moiety, resulted in an increase in both potency and efficacy.

APA, Harvard, Vancouver, ISO, and other styles

9

Govindan, Serengulam V., Gary L. Griffiths, Hans J. Hansen, Ivan D. Horak, and David M. Goldenberg. "Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies." Technology in Cancer Research & Treatment 4, no. 4 (August 2005): 375–91. http://dx.doi.org/10.1177/153303460500400406.

Full text

Abstract:

Radioimmunotherapy and antibody-directed chemotherapy have emerged as cancer treatment modalities with the regulatory approval of products for non-Hodgkin's lymphoma and acute myeloid leukemia. Antibody-toxin therapy is likewise on the verge of clinical fruition. Accumulating evidence suggests that radioimmunotherapy may have the best impact in minimal-disease and adjuvant settings, especially with radioresistant solid tumors. For the latter, ongoing efforts in ‘pretargeting’ to increase deliverable tumor radiation dose, combination therapies, and locoregional applications are also of importan

APA, Harvard, Vancouver, ISO, and other styles

10

Lefeber, Dirk J., Barry Benaissa-Trouw, Johannes F. G. Vliegenthart, Johannis P. Kamerling, Wouter T. M. Jansen, Kees Kraaijeveld, and Harm Snippe. "Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3." Infection and Immunity 71, no. 12 (December 2003): 6915–20. http://dx.doi.org/10.1128/iai.71.12.6915-6920.2003.

Full text

Abstract:

ABSTRACT Oligosaccharide (OS)-protein conjugates are promising candidate vaccinesagainst encapsulated bacteria, such as Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae. Although the effects of several variables such as OS chain length and protein carrier have been studied, little is known about the influence of adjuvants on the immunogenicity of OS-protein conjugates. In this study, a minimal protective trisaccharide epitope of Streptococcus pneumoniae type 3 conjugated to the cross-reacting material of diphtheria toxin was used for immunization of BALB/c mice in t

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antibody-toxin conjugates"

1

Ng, Wai-yun Louisa. "Production of variants of mitogillin with reduced IgE binding activity." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ng, Wai-yun Louisa, and 吳慧欣. "Production of variants of mitogillin with reduced IgE bindingactivity." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kwok, Hon Hung. "Immunolesioning in the rat brain." HKBU Institutional Repository, 1999. http://repository.hkbu.edu.hk/etd_ra/234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"Construction of a Recombinant Immunotoxin." University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/2100/270.

Full text

Abstract:

In recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds to human free kappa light chains and recognises a specif

APA, Harvard, Vancouver, ISO, and other styles

5

"Construction of a recombinant immunotoxin." Thesis, University of Technology, Sydney. Faculty of Science, 1995. http://hdl.handle.net/10453/20069.

Full text

Abstract:

University of Technology, Sydney. Faculty of Science.<br>In recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology. In general, this involves fusion of a toxin gene with sequence encoding a variety of clinically relevant proteins or peptides. Using these techniques a recombinant immunotoxin has been engineered by fusing the genes encoding an antibody fragment with the sequence of a small cytolytic peptide, melittin. The antibody fragment consists of the antigen binding site derived from a murine monoclonal antibody K- 1-21, which binds

APA, Harvard, Vancouver, ISO, and other styles

6

XU, HAO-JI, and 徐鎬基. "Studies on immunotoxin-monoclonal antibody 9.5D-abrin toxin a chain conjugates-against the grith of human cervical cancer cell lines." Thesis, 1991. http://ndltd.ncl.edu.tw/handle/82906099079103529855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antibody-toxin conjugates"

1

Mark, Chamow Steven, and Ashkenazi Avi, eds. Antibody fusion proteins. New York: Wiley-Liss, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

E, Frankel Arthur, ed. Immunotoxins. Boston: Kluwer Academic Publishers, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Phan, Văn Chi. Trichobakin và Immunotoxin tái tổ hợp. Hà Nội: Nhà xuất bản Khoa học tự nhiên và công nghệ, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ramakrishnan, S. Cytotoxic conjugates. Austin: R.G. Landes Co., 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

1960-, Tyle Praveen, and Ram Bhanu P. 1951-, eds. Targeted therapeutic systems. New York: Dekker, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

1947-, Wiley Ronald G., and Lappi Douglas A, eds. Molecular neurosurgery with targeted toxins. Totowa, N.J: Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

A, Lappi Douglas, ed. Suicide transport and immunolesioning. Austin: R.G. Landes, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Frankel, Arthur E. Immunotoxins. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Immunotoxin Methods and Protocols. Humana Press, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Frankel, A. Clinical Applications of Immunotoxins (Current Topics in Microbiology and Immunology). Springer-Verlag Telos, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Antibody-toxin conjugates"

1

Cumber, Alan J., and Edward J. Wawrzynczak. "Preparation of Cytotoxic Antibody—Toxin Conjugates." In Immunochemical Protocols, 135–44. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-257-9_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pietersz, Geoffrey, and Ian McKenzie. "Immunotherapy for Cancer—Toxin-Antibody Conjugates." In Toxins and Targets, 65–74. London: Routledge, 2022. http://dx.doi.org/10.4324/9781315076911-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Neville, David M. "Monoclonal Antibody Mediated Drug Delivery and Antibody Toxin Conjugates." In Directed Drug Delivery, 211–30. Totowa, NJ: Humana Press, 1985. http://dx.doi.org/10.1007/978-1-4612-5186-6_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Blakey, David C., Edward J. Wawrzynczak, Philip M. Wallace, and Philip E. Thorpe. "Antibody Toxin Conjugates: A Perspective (Part 1 of 2)." In Monoclonal Antibody Therapy, 50–70. Basel: KARGER, 1988. http://dx.doi.org/10.1159/000318800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Blakey, David C., Edward J. Wawrzynczak, Philip M. Wallace, and Philip E. Thorpe. "Antibody Toxin Conjugates: A Perspective (Part 2 of 2)." In Monoclonal Antibody Therapy, 71–90. Basel: KARGER, 1988. http://dx.doi.org/10.1159/000318801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Wawrzynczak, Edward J., and Alan J. Cumber. "Immunoaffinity Purification and Quantification of Antibody—Toxin Conjugates." In Immunochemical Protocols, 145–53. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-59259-257-9_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ohtani, Katsumi, and Yoshio Ueno. "Selective Antitumor Activity of T-2 Toxin-Antibody Conjugates." In Microbial Toxins in Foods and Feeds, 403–9. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4613-0663-4_38.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Colombatti, M., M. Bisconti, P. Lorenzi, G. Stevanoni, B. Dipasquale, M. Gerosa, and G. Tridente. "Human Glioma Cell Lines: Tumour Associated Antigens Distribution and Sensitivity to Antibody-Toxin or Ligand-Toxin Conjugates. A Preliminary Report." In Proceedings of the 8th European Congress of Neurosurgery, Barcelona, September 6–11, 1987, 121–25. Vienna: Springer Vienna, 1988. http://dx.doi.org/10.1007/978-3-7091-8978-8_26.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Oldham, Robert K. "Antibody-Drug and Antibody-Toxin Conjugates." In Immunity to Cancer, 575–85. Elsevier, 1985. http://dx.doi.org/10.1016/b978-0-12-586270-7.50053-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

"Antibody Toxin Fusions or Conjugates." In Encyclopedia of Cancer, 268. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-46875-3_100201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antibody-toxin conjugates"

1

Terrett, Jonathan A., Rachel Dusek, Dee Aud, Rahel Awdew, Sudha Swaminathan, San Lin Lou, Michael Trang, et al. "Abstract 661: Proteomics and selecting the right combination of target and toxin for antibody-drug-conjugate (ADC) development." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-661.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rickles, Richard J., Thomas P. Giordano, Shakira F. Cotard, Jill M. Grenier, Angela Romanelli, and Ti Cai. "Abstract 4765: Drug synergies observed for antibody and toxin components of SAR3419 ADC contribute to overall conjugate efficacy and can be combination drug or tumor cell line dependent." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4765.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!